Early-phase expertise CMAX is a leading Australian clinical trial unit specializing in early-phase Phase I-II studies with a 78-bed facility and substantial first-in-human experience, indicating strong capabilities for sponsors seeking early safety and dose-escalation data.

Regulatory maturity With a robust regulatory history, adherence to ICH GCP and requirements from US FDA, EMA, Japan, and Health Canada, plus US FDA audits, CMAX presents a trusted partner for global sponsors requiring compliant, high-quality data across multiple regions.

Large participant pool A database of 70,000+ participants and diverse recruitment capabilities support efficient enrollment for complex early-phase trials, enabling faster study timelines and improved screening success.

Strategic partnerships Recent collaboration with Holoclara Inc alongside Novotech signals active cross-border and CRO partnerships, suggesting growth potential through joint trials and broader therapeutic opportunities.

Growth signals Revenue in the 1–10 million range and a strong market position as one of Australia’s largest clinical trial units indicate scalability potential for additional capacity, expanded services, or broader geographic outreach to attract multinational sponsors.